This article has been updated to include share prices and details.
NEW YORK, Oct. 29 (GenomeWeb News) - Shares in Lynx Therapeutics were down nearly 9 percent at $2.65 in mid-afternoon trade on the Nasdaq exchange after sliding to $2.25 earlier in the day on news that its financial position is more precarious than originally reported.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.
Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.
Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.
In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.